62 related articles for article (PubMed ID: 20678850)
1. Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality.
Taus A; Vollmer I; Arriola E
Arch Bronconeumol; 2011 Feb; 47(2):103-5. PubMed ID: 20678850
[TBL] [Abstract][Full Text] [Related]
2. Impact of EGFR mutation analysis in non-small cell lung cancer.
Yamamoto H; Toyooka S; Mitsudomi T
Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
[TBL] [Abstract][Full Text] [Related]
3. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
[TBL] [Abstract][Full Text] [Related]
4. Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
Riely GJ; Politi KA; Miller VA; Pao W
Clin Cancer Res; 2006 Dec; 12(24):7232-41. PubMed ID: 17189394
[TBL] [Abstract][Full Text] [Related]
5. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
[TBL] [Abstract][Full Text] [Related]
7. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
8. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
9. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
Park SW; Chung NG; Han JY; Eom HS; Yoo NJ; Lee SH
APMIS; 2010 Jan; 118(1):83-4. PubMed ID: 20041876
[No Abstract] [Full Text] [Related]
12. Rare mutations in non-small-cell lung cancer.
D'Arcangelo M; D'Incecco A; Cappuzzo F
Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
[TBL] [Abstract][Full Text] [Related]
13. [ARMS method verified EGFR gene mutations and its clinical significance in patients with non-small cell lung cancer].
Xu HY; Hong WL; Xie SS; Pan XD; Bai YH; Lin XY; Chen BC
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Mar; 30(2):158-60. PubMed ID: 25016871
[No Abstract] [Full Text] [Related]
14. Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties.
Ma L; Wang DD; Huang Y; Wong MP; Lee VH; Yan H
Comput Biol Med; 2015 Aug; 63():293-300. PubMed ID: 25035232
[TBL] [Abstract][Full Text] [Related]
15. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
Mohapatra PR; Punatar S; Prabhash K
Eur Respir J; 2012 Jun; 39(6):1550-1; author reply 1551. PubMed ID: 22654017
[No Abstract] [Full Text] [Related]
16. Tissue Is the Issue for Diagnosis of EGFR T790M Mutation.
Khan J; Pritchard CC; Martins RG
J Thorac Oncol; 2016 Jul; 11(7):e91-2. PubMed ID: 27339415
[No Abstract] [Full Text] [Related]
17. What is the true prevalence of EGFR mutations in India?
Jiwnani S; Karimundackal G; Pramesh CS; Prabhash K
Lung Cancer; 2011 Dec; 74(3):549. PubMed ID: 21996090
[No Abstract] [Full Text] [Related]
18. Germline mutations predisposing to non-small cell lung cancer.
Clamon GH; Bossler AD; Abu Hejleh T; Furqan M
Fam Cancer; 2015 Sep; 14(3):463-9. PubMed ID: 25813228
[TBL] [Abstract][Full Text] [Related]
19. Morphological and genetic classification of lung cancer: variation in practice and implications for tailored treatment.
Cane P; Linklater KM; Nicholson AG; Peake MD; Gosney J
Histopathology; 2015 Aug; 67(2):216-24. PubMed ID: 25545849
[TBL] [Abstract][Full Text] [Related]
20. Whole Brain Radiotherapy for Patients with Non-Small Cell Lung Cancer with EGFR Mutations-Why and When?
Dziadziuszko R
J Thorac Oncol; 2016 Oct; 11(10):1604-5. PubMed ID: 27663395
[No Abstract] [Full Text] [Related]
[Next] [New Search]
